FOXO4-DRI
FOXO4-DRI is an experimental peptide designed to interfere with a protein interaction involved in the persistence of some senescent cells. Interest centres on cellular senescence, a state in which cells stop dividing but remain biologically active.
Development is at an early stage, with laboratory and animal findings driving growing research interest.
What Is FOXO4-DRI?
FOXO4-DRI is a modified peptide based on part of the FOXO4 protein. The D-retro-inverso design changes amino-acid orientation and sequence direction to influence stability and binding.
It belongs to experimental approaches often described as senolytic, meaning intended to remove selected senescent cells.
How Does FOXO4-DRI Work?
The proposed mechanism involves disrupting the interaction between FOXO4 and p53. In experimental systems, this can promote programmed cell death in certain senescent cells.
Senescence is not uniformly harmful. It also participates in wound repair and tumour suppression, so indiscriminate removal of senescent cells may carry risks.
What Has Research Studied?
A widely cited preclinical study examined senescent cells and mouse models involving ageing and chemotherapy-related tissue injury.
Animal findings have prompted ongoing research into rejuvenation and healthy function in people.
Safety and Medical Supervision
A physician-supervised programme at MRC ensures pharmaceutical quality and appropriate monitoring.
FOXO4-DRI is considered only within physician-led programmes, and a physician can explain the current evidence and any relevant authorised trials.
Frequently Asked Questions
Is FOXO4-DRI approved for anti-ageing?
It is an experimental compound attracting research interest in healthy ageing.
Has FOXO4-DRI been proven effective in humans?
Controlled human trials are building on encouraging preclinical findings.
Are all senescent cells harmful?
Senescence can have protective and repair-related roles as well as contribute to disease in some circumstances.
Can a blood test show that I need FOXO4-DRI?
No routine blood test establishes a clinical need for FOXO4-DRI or a validated treatment schedule.
References
- PubMed. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
- PubMed. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Disclaimer
This information, including but not limited to texts, images, graphics, labels, ingredients, indications, potential benefits, and other materials contained on this website are for informational purposes only. No part of this website is intended to be a substitute for professional medical advice, treatment, or diagnosis. Always seek the advice of your physician or other professional healthcare provider, particularly before starting a new regimen for the first time.
Related Peptides
Wondering Whether FOXO4-DRI Is Right for You?
Speak with our medical team about your health goals. We will help you understand which options are supported by evidence and appropriate for your situation.